Az EU nem ert veled egyet.
http://healthcare-in-europe.com/en/news/european-parliament-to-investigate-who-pandemic-scandal.html
"The tentacles of drug company influence are in all levels in the decision-making process,"
http://amp.theguardian.com/business/2010/jun/04/swine-flu-experts-big-pharmaceutical
"The Assembly notes that grave shortcomings have been identified regarding the transparency of decision-making processes relating to the pandemic which have generated concerns about the possible influence of the pharmaceutical industry on some of the major decisions relating to the pandemic"
“Lobbying in a democratic society (European Code of conduct on lobbying)”, the Assembly noted that unregulated or secret lobbying may be a danger and can undermine democratic principles and good governance."
http://www.google.com/amp/s/amp.theguardian.com/world/2010/jan/11/swine-flu-h1n1-vaccine-europe
http://www.pharmatimes.com/news/swine_flu_labelled_a_conspiracy_984175
2011 marcius, Strasbourg, EU:
N. whereas lawsuits were taken in various Member States, alleging corruption and conspiracy on the part of civil servants in relation to contracts signed in summer 2009 between ministries of public health and manufacturers of H1N1 influenza vaccines,
O. whereas, according to the Commission the reluctance of vaccine suppliers to bear full product liability may have contributed to reducing citizens‘ trust in vaccine safety; whereas confidence in vaccines against H1N1 influenza was also undermined by incomplete and contradictory communication on the benefits and risks of vaccination and the potential risks of H1N1 influenza to the public,
T. whereas there is a need for studies on vaccines and antiviral medications that are independent from pharmaceutical companies so as to have a balance between private and publicly funded studies,
18. Underscores the need for studies independent of the pharmaceutical companies on vaccines and antiviral medications, including with regard to the monitoring of vaccination coverage;
19. Wishes to ensure that scientific experts have no financial or other interests in the pharmaceutical industry that could affect their impartiality; requests the development of a European code of conduct relating to the exercise of the function of a scientific expert in any European authority in charge of safety and of the management and anticipation of risks; requires that each expert subscribe to the ethical principles of this code of conduct before taking up his or her duties;
20. Asks that experts who are involved in the pharmaceutical sector, while they may be consulted, should be excluded from decision-making;
26. Recognises that conflicts of interest among experts who advise European public health authorities lead to suspicions of undue influence and harm the overall credibility of these public health authorities and their recommendations; considers that all conflicts of interest must be avoided;
27. Requests the adoption of a definition common to all European public health authorities of what constitutes a conflict of interest;
28. Calls for such conflicts of interest to be brought to Parliament's attention by means of an internal investigation carried out by the Committee on Budgetary Control with a view to determining whether payments to the aforementioned experts were made in a correct and transparent manner and whether the procedures normally employed by the European institutions to forestall such conflicts of interest were followed;
29. Calls for the declarations of interest of all experts who advise the European public health authorities to be published, including those of members of informal groups
http://healthcare-in-europe.com/en/news/european-parliament-to-investigate-who-pandemic-scandal.html
"The tentacles of drug company influence are in all levels in the decision-making process,"
http://amp.theguardian.com/business/2010/jun/04/swine-flu-experts-big-pharmaceutical
"The Assembly notes that grave shortcomings have been identified regarding the transparency of decision-making processes relating to the pandemic which have generated concerns about the possible influence of the pharmaceutical industry on some of the major decisions relating to the pandemic"
“Lobbying in a democratic society (European Code of conduct on lobbying)”, the Assembly noted that unregulated or secret lobbying may be a danger and can undermine democratic principles and good governance."
http://www.google.com/amp/s/amp.theguardian.com/world/2010/jan/11/swine-flu-h1n1-vaccine-europe
http://www.pharmatimes.com/news/swine_flu_labelled_a_conspiracy_984175
2011 marcius, Strasbourg, EU:
N. whereas lawsuits were taken in various Member States, alleging corruption and conspiracy on the part of civil servants in relation to contracts signed in summer 2009 between ministries of public health and manufacturers of H1N1 influenza vaccines,
O. whereas, according to the Commission the reluctance of vaccine suppliers to bear full product liability may have contributed to reducing citizens‘ trust in vaccine safety; whereas confidence in vaccines against H1N1 influenza was also undermined by incomplete and contradictory communication on the benefits and risks of vaccination and the potential risks of H1N1 influenza to the public,
T. whereas there is a need for studies on vaccines and antiviral medications that are independent from pharmaceutical companies so as to have a balance between private and publicly funded studies,
18. Underscores the need for studies independent of the pharmaceutical companies on vaccines and antiviral medications, including with regard to the monitoring of vaccination coverage;
19. Wishes to ensure that scientific experts have no financial or other interests in the pharmaceutical industry that could affect their impartiality; requests the development of a European code of conduct relating to the exercise of the function of a scientific expert in any European authority in charge of safety and of the management and anticipation of risks; requires that each expert subscribe to the ethical principles of this code of conduct before taking up his or her duties;
20. Asks that experts who are involved in the pharmaceutical sector, while they may be consulted, should be excluded from decision-making;
26. Recognises that conflicts of interest among experts who advise European public health authorities lead to suspicions of undue influence and harm the overall credibility of these public health authorities and their recommendations; considers that all conflicts of interest must be avoided;
27. Requests the adoption of a definition common to all European public health authorities of what constitutes a conflict of interest;
28. Calls for such conflicts of interest to be brought to Parliament's attention by means of an internal investigation carried out by the Committee on Budgetary Control with a view to determining whether payments to the aforementioned experts were made in a correct and transparent manner and whether the procedures normally employed by the European institutions to forestall such conflicts of interest were followed;
29. Calls for the declarations of interest of all experts who advise the European public health authorities to be published, including those of members of informal groups
CoronaVirus
https://mobile.twitter.com/hashtag/Wuhan?f=live